unh 近期潜在利好和潜在利空

(I am a UNH shareholder, and my position will inevitably be affected. Please view the content with caution.)
Positive and potential positive factors:
1. Leadership changes.

Veteran Hemsley has taken over as the new CEO. It was he who single-handedly brought UNH to its leading position in the industry, with excellent professional skills and extensive connections accumulated over decades in the industry. On the 23rd, the CFO of UNH's most profitable and core Optum division was also replaced by the company's seasoned local veteran Eklo, who spent over 15 years rising from a grassroots financial manager to today's executive position, deeply familiar with this business.

This change is actually a positive development. The previous CEO, Witty, who resigned, jumped from British pharmaceutical company GlaxoSmithKline in 2018 and became CEO in 2021. Witty himself was severely irresponsible, blindly pursuing scale and expansion speed, and even avoided the office for long periods. Coincidentally, the dismissed CFO of the Optum division also came from the UK. In other words, UNH's CEO and the CFO of its core Optum division are now both local veterans, which is seen as a major move to eliminate the lingering influence of the Witty faction. UNH will break free from the past aggressive pursuit of business scale and a bloated atmosphere, returning to the style of steady growth and high profit margins under Hemsley's leadership.

2. UNH has a rather bizarre aspect in that it has long been friendly with the Republican Party. Before Trump took office, UNH was once considered a Trump concept stock. Healthcare itself heavily relies on official policies, and Hemsley's return to UNH will inevitably leverage his connections. UNH is already seeking a meeting with Trump.

3. Molina and ELV have released their earnings reports and conference calls, both pointing out that the biggest driver of rising medical costs comes from ACA business. Molina's ACA accounts for 10.5%, ELV's ACA business accounts for 15-20%, while UNH's ACA only accounts for 5-8%.

Although ELV's ACA business accounts for 15-20%, its Q3 earnings still exceeded expectations, benefiting from ELV's similar diversified business as the second-largest leader and its successful use of cash flow for acquisitions to hedge against rising costs. Compared to ELV, UNH has a smaller ACA business share, stronger diversified operations, and nine times the free cash flow of ELV.

4. UNH is exiting dozens of unprofitable counties, shifting from pursuing membership growth to pursuing high-quality development, and further controlling costs by revising premium models.

5. 2026 premiums are expected to increase by an average of 5%, ELV by 4-6%, Molina by 5-8%. For UNH, every 1% increase in premiums improves net margins by 0.3%.

6. UNH is working hard to reshape its public image, launching a new AI system to simplify and make the medical claims process more transparent, compressing costs on one hand and also trying to shed its image as a vampire denying claims.

7. In the last conference call, Hemsley deliberately suppressed the stock price by releasing negative news and gave the most conservative expectations under the worst-case scenario. This means this conference call could easily exceed expectations and possibly announce a new buyback plan.

8. In the star ratings, UNH undoubtedly took the crown again.

9. Buffett initiated a position in UNH in Q2.

Negative and potential negative factors:

1. Concerns about persistently rising medical costs. Is the rise in medical costs temporary or persistent? If it's persistent, do healthcare companies have enough ability to hedge against it? Can premium increases cover the cost gap? Molina's conference call pointed out that the number is expected to rise further in 2026, implying medical costs may continue to rise next year.

2. Has the core profit-making Optum division resumed growth? Has Trump's drug procurement policy put potential pressure on the Optum division?

3. Can the ACA policy continue? If not, it will lead to a plunge in Molina (10.5% exposure), CNC (20.66%), and OSCR (94%), dragging down ELV and UNH with pessimism.

(ELV and UNH move highly in sync, as do CNC, Molina, and OSCR.)

4. Can the judicial investigation end as expected with the anticipated settlement? If the settlement exceeds expectations, it will be another negative.

5. Can the conference call deliver a relatively optimistic growth outlook as everyone hopes?

6. Will Buffett increase or liquidate his UNH position in Q3?

$Unitedhealth(UNH.US)